Health Economics›Mantle cell lymphoma›First-line therapy randomized data

First-line therapy randomized data

Mantle cell lymphoma · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
IR-CHOP/R-DHAOx Variant #01	—	R 125 231	21d	—	—	—	—	—
IR-CHOP/R-DHAP Variant #01	—	R 124 333	21d	—	—	—	—	—
R-CHOP Variant #23	—	R 59 865	21d	14.4 mo	55.7 mo	21	R 1 257 163 PFS proxy	3
R-CHOP/R-DHAOx Variant #01	—	R 52 729	21d	—	—	—	—	—
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	51.3 mo	—	56	R 2 285 190 PFS proxy	4
R-Hyper-CVAD/R-MA Variant #01	—	R 22 261	—	—	—	—	—	—
VR-CAP Variant #01	—	R 16 757	21d	24.7 mo	90.7 mo	36	R 603 242 PFS proxy	2
R-CHOP/R-DHAP Variant #01	—	R 16 444	21d	—	—	—	—	—
R-CHOP-14 (Prednisolone) Variant #01	—	R 12 674	14d	—	—	—	—	1
R-CHOP (Prednisolone) Variant #01	—	R 12 666	21d	42.4 mo	—	62	R 785 263 PFS proxy	—
R-CVP Variant #01	—	R 12 182	21d	—	—	—	—	1

11 of 11 regimens shown